Journal article
Ocular melanoma: what's new?
- Leyvraz S Centre Pluridisciplinaire d'Oncologie, University Hospital, Lausanne, Switzerland.
- Keilholz U
- 2012-01-12
Published in:
- Current opinion in oncology. - 2012
Angiogenesis Inhibitors
Antibodies, Monoclonal
Antineoplastic Agents
Chemotherapy, Adjuvant
Clinical Trials as Topic
GTP-Binding Protein alpha Subunits
GTP-Binding Protein alpha Subunits, Gq-G11
Humans
Melanoma
Mitogen-Activated Protein Kinases
Signal Transduction
Uveal Neoplasms
English
PURPOSE OF REVIEW
The purpose of this review was to summarize available data on uveal melanoma biology and treatment in order to provide the medical community with a basic reference that would help to make further progress in this rare disease, which remains difficult to treat.
RECENT FINDINGS
The most relevant recent findings driving current clinical developments are in the elucidation of uveal melanoma genetics and genomics. The key driving mutations - that differ completely from cutaneous melanoma - have been identified. Based on the novel insights into key signaling pathways, the first clinical trials with targeted treatments have been implemented. However, systemic and regional chemotherapy approaches as well as other regional treatment modalities for liver metastases are also a major part of the current treatment armamentarium and are prospectively being evaluated.
SUMMARY
In summary, the recent biological findings and the creation of a series of clinical trials underscore how the international community is able to perform relevant advances in an extremely rare disease.
The purpose of this review was to summarize available data on uveal melanoma biology and treatment in order to provide the medical community with a basic reference that would help to make further progress in this rare disease, which remains difficult to treat.
RECENT FINDINGS
The most relevant recent findings driving current clinical developments are in the elucidation of uveal melanoma genetics and genomics. The key driving mutations - that differ completely from cutaneous melanoma - have been identified. Based on the novel insights into key signaling pathways, the first clinical trials with targeted treatments have been implemented. However, systemic and regional chemotherapy approaches as well as other regional treatment modalities for liver metastases are also a major part of the current treatment armamentarium and are prospectively being evaluated.
SUMMARY
In summary, the recent biological findings and the creation of a series of clinical trials underscore how the international community is able to perform relevant advances in an extremely rare disease.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1097/CCO.0b013e32834ff069
- PMID 22234256
- Persistent URL
- https://sonar.ch/global/documents/20143
Statistics
Document views: 26
File downloads: